Sui Donglin, Li Mingxin, Ai Chunqing, Li Shugang, Chang Hong, Li Yixuan, Zhao Shouhao, Li Huan, Ren Xiaomeng
State Key Laboratory of Marine Food Processing and Safety Control, National Engineering Research Center of Seafood, School of Food Science and Technology, Dalian Polytechnic University, Dalian, Liaoning 116034, China.
State Key Laboratory of Marine Food Processing and Safety Control, National Engineering Research Center of Seafood, School of Food Science and Technology, Dalian Polytechnic University, Dalian, Liaoning 116034, China.
Int J Biol Macromol. 2025 May;307(Pt 3):142263. doi: 10.1016/j.ijbiomac.2025.142263. Epub 2025 Mar 18.
This study aimed to investigate the therapeutic efficacy of Larimichthys Crocea Isinglass polysaccharide (CIP) in ameliorating DSS-induced colitis. CIP, a complex polysaccharide composed of six monosaccharides with a molecular weight of 3.97 kDa. Specifically, CIP treatment mitigated weight loss and histopathological damage in the colon, increased colon length, and by inhibiting the TLR4/MyD88/NF-κB pathway significantly downregulated the secretion levels of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β, while simultaneously upregulating the anti-inflammatory cytokine IL-10 and inhibition of the oxidative stress-related enzyme inducible nitric oxide synthase (iNOS). Additionally, CIP treatment enhanced intestinal barrier function by increasing the expression of intestinal tight junction proteins (TJs) and MUC2, and it promoted the production of short-chain fatty acids (SCFAs). Concurrently, CIP modulated the composition of the intestinal microbiota, inhibiting the proliferation of potentially harmful bacteria such as Bacteroidota and Campylobacter. Taken together, these findings suggest that CIP exhibits promising attributes as a functional food constituent, with a particular efficacy in modulating and maintaining intestinal health.
本研究旨在探讨大黄鱼鳔多糖（CIP）改善葡聚糖硫酸钠（DSS）诱导的结肠炎的治疗效果。CIP是一种由六种单糖组成的复合多糖，分子量为3.97 kDa。具体而言，CIP治疗减轻了体重减轻和结肠的组织病理学损伤，增加了结肠长度，并通过抑制TLR4/MyD88/NF-κB途径显著下调促炎细胞因子TNF-α、IL-6和IL-1β的分泌水平，同时上调抗炎细胞因子IL-10并抑制氧化应激相关酶诱导型一氧化氮合酶（iNOS）。此外，CIP治疗通过增加肠道紧密连接蛋白（TJ）和MUC2的表达增强了肠道屏障功能，并促进了短链脂肪酸（SCFA）的产生。同时，CIP调节肠道微生物群的组成，抑制拟杆菌门和弯曲杆菌等潜在有害细菌的增殖。综上所述，这些发现表明CIP作为一种功能性食品成分具有良好的特性，在调节和维持肠道健康方面具有特殊功效。
